Biogenes Technologies: Changing Biotech With Synthetic Antibodies

Biogenes Technologies is trying to change the biotech landscape by creating and commercialising synthetic antibodies for mass use in all kinds of test kits. However building and scaling a deeptech startup like this can be challenging here in Malaysia without the right help.

We speak to Adrian Joseph, Co-Founder & Chief Commercial Officer, of Biogenes Technologies about the startup’s journey and mission, and how Cradle Fund has supported them along the way.